Organic Letters
Letter
a
Scheme 3. Reactivity of Various Amines in the Sequence
REFERENCES
■
(1) (a) Molander, G. A.; Harris, C. R. Chem. Rev. 1996, 96, 307.
(b) Albrecht, Ł.; Jiang, H.; Jørgensen, K. A. Angew. Chem., Int. Ed. 2011,
50, 8492. (c) Marson, C. M. Chem. Soc. Rev. 2012, 41, 7712. (d) Zeng, X.
Chem. Rev. 2013, 113, 6864.
(2) (a) Catellani, M.; Motti, E.; Della Ca’, N. Acc. Chem. Res. 2008, 41,
1512. (b) Dobrounig, P.; Trobe, M.; Breinbauer, R. Monatsh. Chem.
2017, 148, 3.
(3) (a) Plevyak, J. E.; Heck, R. F. J. Org. Chem. 1978, 43, 2454.
(b) Plevyak, J. E.; Dickerson, J. E.; Heck, R. F. J. Org. Chem. 1979, 44,
4078. (c) Tao, W.; Nesbitt, S.; Heck, R. F. J. Org. Chem. 1990, 55, 63.
́ ́
(4) (a) Baudoin, O.; Cesario, M.; Guenard, D.; Gueritte, F. J. Org.
Chem. 2002, 67, 1199. (b) Billingsley, K. L.; Barder, T. E.; Buchwald, S.
L. Angew. Chem., Int. Ed. 2007, 46, 5359. (c) Molander, G. A.; Trice, S. L.
J.; Kennedy, S. M. J. Org. Chem. 2012, 77, 8678. (d) Jong, H.; Eey, S. T.
C.; Lim, Y. H.; Pandey, S.; Iqbal, N. A. B.; Yong, F. F.; Robins, E. G.;
Johannes, C. W. Adv. Synth. Catal. 2017, 359, 616.
(5) (a) Kaswasaki, I.; Yamashita, M.; Ohta, S. J. Chem. Soc., Chem.
Commun. 1994, 2085. (b) Handy, S. T.; Sabatini, J. J. Org. Lett. 2006, 8,
a
1537. (c) Varello, S.; Handy, S. T. Synthesis 2009, 2009, 138. (d) Tung,
̀
Conditions: 2.5 mmol of NaOt-Bu, 1.0 mmol of aryl-dihalide, 1.1 mmol
of benzophenone imine, 1.1 mmol of amine, 1.2 mol % of C1 and
1.2 mol % of L2, 0.25 M THF, 1.5 h at 22 °C followed by 12 h at 80 °C.
̂
Đ. T.; Tuan, Đ. T.; Rasool, N.; Villinger, A.; Reinke, H.; Fischer, C.;
Langer, P. Adv. Synth. Catal. 2009, 351, 1595. (e) Fyfe, J. W. B.;
Fazakerley, N. J.; Watson, A. J. B. Angew. Chem., Int. Ed. 2017, 56, 1249.
(6) (a) Zhang, X.; Xie, W.; Chen, W. Tetrahedron 2010, 66, 1188.
(b) Cotugno, P.; Monopoli, A.; Ciminale, F.; Cioffi, N.; Nacci, A. Org.
Biomol. Chem. 2012, 10, 808.
(7) Zhang, X.; Liu, A.; Chen, W. Org. Lett. 2008, 10, 3849.
(8) Danodia, A. K.; Saunthwal, R. K.; Patel, M.; Tiwari, R. K.; Verma, A.
K. Org. Biomol. Chem. 2016, 14, 6487.
b
Yields reported: isolated. The amine was added after 2 h at 22 °C.
Brigatinib, a novel commercial oncology drug with ALK and
EGFR inhibitory functions (Scheme 4). The imine-protected
product was isolated by simple extraction and recrystallization
from methanol as a stable solid in good yield (75%) on 1 g scale.
However, further process optimization could be possible.
(9) Pan, S.; Ma, X.; Zhong, D.; Chen, W.; Liu, M.; Wu, H. Adv. Synth.
Catal. 2015, 357, 3052.
(10) Paumo, H.; Makhafola, T.; Mphahlele, M. Molecules 2016, 21,
1366.
Scheme 4. Synthesis of Brigatinib Precursor
(11) (a) Dahl, T.; Tornøe, C. W.; Bang-Andersen, B.; Nielsen, P.;
Jørgensen, M. Angew. Chem., Int. Ed. 2008, 47, 1726. (b) Jensen, T.;
Pedersen, H.; Bang-Andersen, B.; Madsen, R.; Jørgensen, M. Angew.
Chem., Int. Ed. 2008, 47, 888. (c) Ueno, A.; Kitawaki, T.; Chida, N. Org.
Lett. 2008, 10, 1999. (d) Christensen, H.; Schjøth-Eskesen, C.; Jensen,
M.; Sinning, S.; Jensen, H. H. Chem. - Eur. J. 2011, 17, 10618.
(12) (a) Kawaguchi, K.; Nakano, K.; Nozaki, K. Org. Lett. 2008, 10,
1199. (b) Qian, H.; Yue, W.; Zhen, Y.; Di Motta, S.; Di Donato, E.;
Negri, F.; Qu, J.; Xu, W.; Zhu, D.; Wang, Z. J. Org. Chem. 2009, 74, 6275.
(c) Tsvelikhovsky, D.; Buchwald, S. L. J. Am. Chem. Soc. 2010, 132,
14048.
(13) (a) Lin, Y.-H.; Wu, H.-H.; Wong, K.-T.; Hsieh, C.-C.; Lin, Y.-C.;
Chou, P.-T. Org. Lett. 2008, 10, 3211. (b) Yang, C.-H.; Prabhakar, C.;
Huang, S.-L.; Lin, Y.-C.; Tan, W. S.; Misra, N. C.; Sun, W.-T.; Yang, J.-S.
Org. Lett. 2011, 13, 5632. (c) Dai, W.; Li, J.; Li, G.; Yang, H.; Wang, L.;
Gao, S. Org. Lett. 2013, 15, 4138. (d) Tan, Y.; Liang, M.; Lu, Z.; Zheng,
Y.; Tong, X.; Sun, Z.; Xue, S. Org. Lett. 2014, 16, 3978.
In summary, we have developed an efficient and versatile pro-
tocol for the one-pot sequential multicomponent preparation of
a class of amino-anilines and their derivatives. Many (hetero)aryl
substrates were successfully aminated with a range of biologically
active secondary amines using the recently discovered Pd-allyl
complexes27 as air- and moisture-stable precatalysts. Practical
utility of the process was demonstrated on a gram-scale synthesis
of a major building block for Brigatinib.
(14) (a) Brasca, M. G.; Amboldi, N.; Ballinari, D.; Cameron, A.; Casale,
E.; Cervi, G.; Colombo, M.; Colotta, F.; Croci, V.; D’Alessio, R.; et al. J.
Med. Chem. 2009, 52, 5152. (b) Behrens, C. H.; Lei, Y.; Li, H. Y.
WO2012012139 A1, 2012. (c) Huang, W.-S.; Liu, S.; Zou, D.; Thomas,
M.; Wang, Y.; Zhou, T.; Romero, J.; Kohlmann, A.; Li, F.; Qi, J.; et al. J.
Med. Chem. 2016, 59, 4948. (d) Liu, Z.; Tang, L.; Zhu, H.; Xu, T.; Qiu,
C.; Zheng, S.; Gu, Y.; Feng, J.; Zhang, Y.; Liang, G. J. Med. Chem. 2016,
59, 4637. (e) Lee, L. Y.; Hernandez, D.; Rajkhowa, T.; Smith, S. C.;
Raman, J. R.; Nguyen, B.; Small, D.; Levis, M. Blood 2017, 129, 257.
(15) (a) Erdman, D. T.; Flamme, C. M.; Nelson, J. D. WO 2008032157
A2, 2008. (b) Sun, C.-Y.; Li, Y.-S.; Shi, A.-L.; Li, Y.-F.; Cao, R.-F.; Ding,
H.-W.; Yin, Q.-Q.; Zhang, L.-J.; Zheng, H.-C.; Song, H.-R. Chin. Chem.
Lett. 2015, 26, 1307. (c) Levy, D. V.; Sclafani, J. A.; Bakale, R. P. Org.
Process Res. Dev. 2016, 20, 2085.
ASSOCIATED CONTENT
* Supporting Information
The Supporting Information is available free of charge on the
■
S
Experimental procedures and characterization data (PDF)
AUTHOR INFORMATION
Corresponding Author
■
ORCID
(16) Ono, N. The Nitro Group in Organic Synthesis; Wiley-VCH: New
Notes
York, 2001; pp 1−392.
(17) Brown, D. G.; Bostrom, J. J. Med. Chem. 2016, 59, 4443.
̈
The authors declare the following competing financial interest(s):
(18) (a) Surry, D. S.; Buchwald, S. L. Chem. Sci. 2011, 2, 27.
Catalysts and organic intermediates will be made commercial.
(b) Johansson Seechurn, C. C. C.; Kitching, M. O.; Colacot, T. J.;
D
Org. Lett. XXXX, XXX, XXX−XXX